UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report - September 12, 2003
(Date of earliest event reported)
Hemispherx Biopharma, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-27072 52-0845822
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification
Number)
1617 JFK Boulevard 19103
(Address of principal executive offices) (Zip Code)
Area Code (215) 988-0080
(Registrant's telephone number
1
Item 5. Other Events
At the Company's Annual Meeting of Stockholders on September 10, 2003,
stockholders approved the following:
Total shares voted: 27,003,653 out of 35,821,275 eligible to vote.
Election of Directors:
For Withheld
William A. Carter, M.D. 22,344,867 4,658,786
Richard C. Piani, Esq. 24,899,018 2,104,635
Ransom W. Etheridge, Esq. 22,942,478 4,061,175
William M. Mitchell. Ph.D., M.D. 23,903,718 3,099,935
Iraj-Eqhbal Kiani, Ph.D. 24,269,933 2,733,720
Ratification of the selection of BDO Seidman, LLP, as independent auditors of
Hemispherx Biopharma, Inc. for the year ending December 31, 2003.
For: 25,033,555 Against: 1,960,625 Abstain: 9,473
Amend the Company's Certificate of Incorporation to increase the authorized
shares of common stock from 50,000,000 to 100,000,000.
For: 24,695,036 Against: 2,298,867 Abstain: 9,750